Work

Imatinib is not a potent anti-SARS-CoV-2 drug

Year: 2020

Type: article

Source: Leukemia

DOI: 10.1038/s41375-020-01045-9

Authors: Helong Zhao, Michelle Mendenhall, Michael W. Deininger

Institutions: University of Utah, Huntsman Cancer Institute, Utah State University

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Health and Human Services, Huntsman Cancer Institute, National Institutes of Health, National Cancer Institute

Awards: G1192507251, G1517530671, G2636606427, G368171078, Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia, American Indian/Alaskan Native Think Tank, G7593044622, G828319272, G858682239, G9000041161

OpenAlex ID: W3091228967

FWCI: 1.117

Cites: 18

Cited by: 39

Related to: 10